156 related articles for article (PubMed ID: 30998196)
1. [Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
Padelli M; Bruno C; Lemarchand J; Vourc'h P; Andres C; Blasco H; Benz-de Bretagne I
Ann Biol Clin (Paris); 2019 Apr; 77(2):161-168. PubMed ID: 30998196
[TBL] [Abstract][Full Text] [Related]
2. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
5. Validation of HPLC-amperometric detection to measure serotonin in plasma, platelets, whole blood, and urine.
Pussard E; Guigueno N; Adam O; Giudicelli JF
Clin Chem; 1996 Jul; 42(7):1086-91. PubMed ID: 8674193
[TBL] [Abstract][Full Text] [Related]
6. Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.
Joish VN; Shah S; Tierce JC; Patel D; McKee C; Lapuerta P; Zacks J
Future Oncol; 2019 Apr; 15(12):1397-1406. PubMed ID: 30734573
[No Abstract] [Full Text] [Related]
7. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin.
Kema IP; de Vries EG; Schellings AM; Postmus PE; Muskiet FA
Clin Chem; 1992 Apr; 38(4):534-40. PubMed ID: 1373675
[TBL] [Abstract][Full Text] [Related]
8. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors.
Meijer WG; Kema IP; Volmer M; Willemse PH; de Vries EG
Clin Chem; 2000 Oct; 46(10):1588-96. PubMed ID: 11017936
[TBL] [Abstract][Full Text] [Related]
9. Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
Sen Gupta P; Grozinsky-Glasberg S; Drake WM; Akker SA; Perry L; Grossman AB; Druce MR
Clin Endocrinol (Oxf); 2014 Feb; 80(2):246-52. PubMed ID: 23790044
[TBL] [Abstract][Full Text] [Related]
10. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
12. Role of biomarker tests for diagnosis of neuroendocrine tumours.
Hofland J; Zandee WT; de Herder WW
Nat Rev Endocrinol; 2018 Nov; 14(11):656-669. PubMed ID: 30158549
[TBL] [Abstract][Full Text] [Related]
13. Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.
Johansen SU; Hansen T; Nordborg A; Meyer R; Goll R; Florholmen J; Jensen E
J Neuroendocrinol; 2024 Mar; 36(3):e13372. PubMed ID: 38361341
[TBL] [Abstract][Full Text] [Related]
14. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
[TBL] [Abstract][Full Text] [Related]
15. Urinary serotonin in the diagnosis of carcinoid tumors.
Feldman JM
Clin Chem; 1986 May; 32(5):840-4. PubMed ID: 2421946
[TBL] [Abstract][Full Text] [Related]
16. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
de Mestier L; Savagner F; Brixi H; Do Cao C; Dominguez-Tinajero S; Roquin G; Goichot B; Hentic O; Dubreuil O; Hautefeuille V; Walter T; Cadiot G
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1673-e1682. PubMed ID: 33382891
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Lewis AR; Wang X; Magdalani L; D'Arienzo P; Bashir C; Mansoor W; Hubner R; Valle JW; McNamara MG
World J Gastroenterol; 2018 Feb; 24(6):671-679. PubMed ID: 29456406
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and outcome of type 3 gastric neuroendocrine tumours.
Min BH; Hong M; Lee JH; Rhee PL; Sohn TS; Kim S; Kim KM; Kim JJ
Br J Surg; 2018 Oct; 105(11):1480-1486. PubMed ID: 29893418
[TBL] [Abstract][Full Text] [Related]
20. Serotonin in blood: assessment of its origin by concomitant determination of β-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells).
Zeinali F; Fossmark R; Hauso Ø; Wiseth R; Hjertner Ø; Waldum HL
Scand J Clin Lab Invest; 2013 Mar; 73(2):148-53. PubMed ID: 23327100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
